|
|
Chronic myeloid leukemia (CML) pipeline updatePublished by: Datamonitor Published: Nov. 7, 2002 - 42 Pages Table of ContentsOverview Introduction With CML’s relatively low prevalence, the potential market for drugs launched for this indication historically has been insufficient in size to allow companies to rapidly recoup their investment. Accordingly, only a handful of drugs have been approved for chronic leukemia in the last decade. However, since the launch of Novartis’ Gleevec (imatinib mesylate), significant revenues have been accrued, drawing industry attention to the CML market. Scope Provides a full breakdown of the Gleevec sales phenomenon, with detailed explanations and analysis. Looks at the CML pipeline and provides product profiles, clinical data and forecast revenues to 2010. Assesses the CML market’s future based on the attention that Gleevec has provided and where the attention will likely move in the future. Report Highlights Genta/Aventis’ Genasense (augmerosen) is forecast significant revenues in CML due to its chemosensitizing activity with most cytotoxic agents. Reasons to Purchase Access insights into the developmental gains available through CML and into the path to a successful revenue stream. Identify how targeting CML can provide significant sales gains through off-label usage in AML. Define the gaps in the CML market opening via Gleevec-resistant patient populations, and identify new opportunities for drug development. Report Highlights Gleevec resistance in blast phase CML will provide new products with opportunity to gain market share and establish a strong position. The CML market represents a strong market for future development, however most of the lucrative revenue streams can be found through off-label drug usage in the acute leukemias. INTRODUCTION TO CHRONIC MYELOID LEUKEMIA A description of chronic myeloid leukemia (CML), its market and historic therapies GLEEVEC CASE STUDY Analysis of the developmental and market strategies that have contributed to the success of Gleevec CML PIPELINE Overview of the key compounds in development for CML, with forecasts to 2010 Decitabine Genasense PEG-Intron THE FUTURE CML MARKET An assessment of the dynamics of the CML market DATASETS Table 1: Current gold-standard therapies for CML, 2002 Table 2: Quarterly sales data for Gleevec since launch Table 3: Global forecasts for Gleevec, 2002-2010 Table 4: Late-stage developmental compounds for CML, 2002 Table 5: The number of compounds in development for the differing leukemia indications, 2002 Table 6: Global forecasts for decitabine, 2004-2010 Table 7: Global forecasts for Genasense, 2004-2010 Figure 1: The typical progression of CML Figure 2: Gleevec’s proposed mechanism of action Figure 3: Comparison of the niche and major markets, and the benefits that each hold Figure 4: The underlying strategies that Novartis has undertaken to market Gleevec Figure 5: Key factors in the relative success of decitabine Figure 6: Key factors in the relative success of Genasense Figure 7: Key factors in the relative success of PEG-Intron AbstractIntroduction: With CML's relatively low prevalence, the potential market for drugs launched for this indication historically has been insufficient in size to allow companies to rapidly recoup their investment. Accordingly, only a handful of drugs have been approved for chronic leukemia in the last decade. However, since the launch of Novartis' Gleevec (imatinib mesylate), significant revenues have been accrued, drawing industry attention to the CML market. Scope: * Provides a full breakdown of the Gleevec sales phenomenon, with detailed explanations and analysis. * Looks at the CML pipeline and provides product profiles, clinical data and forecast revenues to 2010. * Assesses the CML market's future based on the attention that Gleevec has provided and where the attention will likely move in the future. Report Highlights: Genta/Aventis' Genasense (augmerosen) is forecast significant revenues in CML due to its chemosensitizing activity with most cytotoxic agents. Gleevec resistance in blast phase CML will provide new products with opportunity to gain market share and establish a strong position. The CML market represents a strong market for future development, however most of the lucrative revenue streams can be found through off-label drug usage in the acute leukemias. Reasons to Purchase: * Access insights into the developmental gains available through CML and into the path to a successful revenue stream. * Identify how targeting CML can provide significant sales gains through off-label usage in AML. * Define the gaps in the CML market opening via Gleevec-resistant patient populations, and identify new opportunities for drug development.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||